CDMO Catalent has announced the addition of DPI capsule filling capacity for potent drugs at its facility in the Boston, MA, USA area, including isolators for processing of potent compounds and cleanroom upgrades. According to Catalent, spray drying capacity has also increased, giving the company the largest cGMP manufacturing capacity for DPI capsules.
The CDMO acquired the facility in Chelsea, MA from Acorda in 2021, and the location is now the company’s Global Center of Excellence for inhaled dry powder spray drying, capsule filling, and packaging. Another Catalent facility, in Morrisville, NC, USA, which houses inhalation formulation development, completed an upgrade of nasal spray manufacturing capacity in 2022.
The Boston site’s General Manager, Gordon Ashton, commented, “We are delighted that we are now able to handle potent drugs in Boston and do so in a low relative humidity, less than 10%, environment to maintain powder stability with strict microbial controls. The site’s annual capacity has increased to 300 million capsules, one-third of which can be employed for potent drugs.”
Read the Catalent press release.
